infant
young
children
acut
otiti
media
aom
frequent
diagnosi
offic
set
studi
conduct
center
diseas
control
prevent
annual
number
offic
visit
aom
unit
state
increas
million
million
addit
rate
tympanostomi
tube
placement
increas
approxim
fourfold
estim
direct
indirect
cost
treat
otiti
media
children
year
age
unit
state
billion
dollar
studi
infant
paradis
et
al
found
year
life
antibiot
aom
given
mean
day
middl
ear
effus
mee
present
time
tympanostomi
tube
insert
infant
respect
year
age
children
experienc
least
one
episod
mee
children
develop
first
episod
aom
month
age
like
develop
recurr
diseas
addit
young
age
risk
factor
often
associ
frequent
episod
aom
includ
male
gender
race
eg
nativ
american
genet
predisposit
eg
sibl
frequent
aom
underli
medic
condit
eg
cleft
palat
low
socioeconom
statu
daycar
attend
exposur
cigarett
smoke
household
lack
breast
feed
eustachian
tube
et
protect
middl
ear
invad
organ
mucociliari
system
secret
antimicrobi
substanc
defensin
lactoferrin
lysozym
surfact
addit
serum
antibodi
transud
middl
ear
caviti
protect
specif
bacteri
pathogen
defens
may
disrupt
respiratori
virus
lead
impair
et
function
chinchilla
model
influenza
caus
epitheli
damag
accumul
cellular
mucu
debri
lumen
et
subsequ
neg
middl
ear
pressur
similar
evid
et
dysfunct
substanti
studi
children
abnorm
tympanogram
occur
children
clinic
symptom
upper
respiratori
infect
uri
abnorm
detect
day
ill
appear
respiratori
virus
affect
et
function
induc
releas
variou
cytokin
inflammatori
mediat
epitheli
cell
addit
et
dysfunct
respiratori
virus
immunosuppress
effect
polymorphonuclear
cell
increas
adher
bacteria
epitheli
cell
adenoviru
increas
bind
streptococcu
pneumonia
influenza
viru
induc
increas
bind
pneumonia
haemophilu
influenza
human
epitheli
cell
numer
studi
confirm
strong
relationship
viral
uri
aom
viral
uri
aom
share
mani
risk
factor
includ
season
young
age
daycar
attend
aom
peak
onset
day
onset
viral
uri
despit
close
associ
previou
studi
gener
detect
virus
approxim
middl
ear
fluid
specimen
children
aom
recent
studi
heikkinen
et
al
evalu
preval
respiratori
virus
middl
ear
fluid
incid
acut
otiti
media
aom
infant
young
children
increas
dramat
recent
year
unit
state
aom
often
follow
upper
respiratori
tract
infect
due
pathogen
respiratori
syncyti
viru
rsv
influenza
viru
parainfluenza
viru
piv
virus
caus
eustachian
tube
dysfunct
critic
pathogenesi
aom
vaccin
virus
would
like
reduc
incid
aom
three
previou
studi
influenza
viru
vaccin
reduc
incid
aom
vaccin
prevent
infect
rsv
piv
type
undergo
clinic
test
time
streptococcu
pneumonia
nontyp
haemophilu
influenza
nthi
moraxella
catarrhali
three
common
aom
pathogen
heptaval
pneumococc
conjug
vaccin
effect
prevent
invas
diseas
aom
caus
serotyp
contain
vaccin
vaccin
candid
nthi
catarrhali
develop
children
age
month
year
among
children
respiratori
syncyti
viru
rsv
detect
nasal
wash
specimen
viru
middl
ear
fluid
correspond
proport
children
parainfluenza
viru
piv
influenza
viru
enteroviru
three
adenoviru
one
among
middl
ear
sampl
virus
isol
virus
bacteria
found
togeth
ear
wherea
virus
sole
middleear
pathogen
ear
use
revers
transcriptasepolymerasechain
reaction
rtpcr
pitkaranta
et
al
detect
viral
rna
nasal
aspir
mee
episod
aom
children
posit
nasal
aspir
cultur
rhinoviru
rna
found
middleear
fluid
specimen
rsv
coronaviru
vaccin
prevent
common
respiratori
ill
also
like
prevent
aom
acut
otiti
media
commonli
associ
influenza
infect
yet
licens
vaccin
wide
administ
healthi
infant
young
children
efficaci
influenza
vaccin
prevent
aom
evalu
three
previou
studi
first
studi
heikkinen
et
al
administ
trival
influenza
vaccin
children
age
year
daycar
center
gave
vaccin
anoth
children
eight
differ
daycar
center
finland
influenza
season
children
seen
clinic
fever
sign
uri
investig
blind
case
know
child
vaccin
influenza
occur
five
vaccine
control
subject
efficaci
vaccin
influenza
influenzaassoci
aom
aom
diagnos
vaccine
control
subject
repres
reduct
episod
aom
due
influenza
vaccin
second
studi
clement
et
al
evalu
children
age
month
enrol
eight
daycar
center
north
carolina
particip
enrol
randomli
assign
trival
influenza
vaccin
hepat
b
vaccin
children
given
vaccin
new
children
enrol
receiv
influenza
vaccin
ear
examin
parent
request
ear
examin
random
children
examin
biweekli
blind
investig
respiratori
season
peak
influenza
season
aom
diagnos
children
given
influenza
vaccin
children
given
hepat
b
vaccin
vaccin
unadjust
reduct
incid
aom
p
mee
p
third
multicent
doubleblind
random
studi
live
coldadapt
trival
influenza
vaccin
placebo
ratio
administ
intranas
children
age
month
children
seen
investig
symptom
consist
influenza
diseas
occur
aom
primari
endpoint
trial
thu
case
definit
use
fourteen
vaccine
placebo
recipi
develop
influenza
efficaci
rate
ci
influenza
vaccin
reduc
incid
febril
aom
ci
studi
one
methodolog
limit
includ
inadequ
sampl
size
lack
random
inadequ
blind
passiv
surveil
influenza
aom
andor
lack
standard
criteria
definit
aom
despit
methodolog
flaw
influenza
vaccin
shown
reduc
incid
aom
similar
proport
studi
address
limit
studi
conduct
doubleblind
efficaci
trial
approxim
children
age
month
randomli
assign
ratio
receiv
inactiv
trival
influenza
vaccin
fluzon
aventi
pasteur
swiftwat
pa
placebo
period
addit
schedul
visit
parent
instruct
contact
us
sign
symptom
respiratori
infect
aom
strict
case
definit
use
diagnos
aom
mee
use
pneumat
otoscopi
tympanometri
spectral
gradient
acoust
reflectometri
videootoscopi
comput
captur
imag
tympan
membran
save
electron
databas
detect
influenza
diseas
viral
throat
cultur
obtain
febril
respiratori
ill
aom
also
nasopharyng
colon
penicillinresist
pneumonia
monitor
throughout
trial
data
still
blind
write
howev
cohort
preliminari
result
show
least
one
episod
aom
develop
children
respiratori
season
mean
episodeschild
children
followup
period
mean
episodeschild
cultureproven
influenza
occur
children
first
cohort
pneumonia
isol
nasopharyng
cultur
children
posit
cultur
child
penicillin
resist
minim
inhibitori
concentr
mic
four
cefotaxim
resist
mic
addit
influenza
vaccin
respiratori
virus
would
like
prevent
aom
young
children
common
upper
lower
respiratori
viru
young
children
rsv
vaccin
prevent
rsv
need
effect
infant
less
month
age
diseas
sever
develop
vaccin
problemat
neonat
poor
immunolog
respons
viral
surfac
glycoprotein
respons
hamper
presenc
matern
antibodi
rsv
signific
antigen
divers
previou
studi
formalininactiv
rsv
vaccin
led
enhanc
diseas
children
later
expos
wildtyp
viru
evid
antibodi
rsv
prevent
aom
observ
infant
given
rsv
immun
globulin
intraven
immunoglobulin
prepar
significantli
reduc
overal
incid
aom
rsvassoci
aom
recent
vaccin
candid
develop
use
coldadapt
cp
temperaturesensit
ts
strain
advantag
intranas
administ
live
attenu
strain
mimic
natur
infect
induc
cellular
humor
immun
replic
mucos
surfac
even
presenc
matern
antibodi
develop
strain
difficult
overor
underattenu
genet
instabl
two
candid
vaccin
attenu
genet
stabl
immunogen
chimpanze
highli
attenu
human
adult
immunogen
seroneg
children
howev
strain
shed
high
titer
transmit
seroneg
placebo
recipi
frequenc
anoth
candid
vaccin
cptsrsv
safe
immunogen
seroneg
children
greater
month
age
caus
nasal
congest
infant
age
week
anoth
strategi
develop
live
rsv
vaccin
infecti
clone
rsv
deriv
use
cdna
mutat
introduc
specif
gene
delet
produc
ideal
strain
proper
balanc
attenu
immunogen
genet
stabil
subunit
vaccin
contain
f
g
glycoprotein
rsv
develop
use
older
children
adult
current
infant
candid
vaccin
experi
formalininactiv
vaccin
induc
enhanc
diseas
vaccine
later
expos
wildtyp
rsv
f
glycoprotein
display
less
antigen
variat
strain
immunogen
g
glycoprotein
two
form
purifi
f
glycoprotein
subunit
vaccin
evalu
clinic
trial
studi
children
month
age
previous
hospit
rsv
infect
vaccin
safe
immunogen
followup
period
protect
vaccine
clinic
rsv
diseas
investig
confirm
safeti
immunogen
vaccin
children
signific
increas
antibodi
f
glycoprotein
although
vaccin
alway
protect
subsequ
rsv
infect
similar
subunit
vaccin
proven
safe
immunogen
children
bronchopulmonari
dysplasia
children
cystic
fibrosi
elderli
popul
children
bronchopulmonari
dysplasia
vaccin
protect
subsequ
rsv
infect
contrast
formalininactiv
rsv
vaccin
vaccin
induc
enhanc
diseas
vaccine
infect
wildtyp
rsv
expand
clinic
trial
subunit
vaccin
ongo
children
adult
parainfluenza
viru
anoth
common
caus
upper
lower
respiratori
diseas
infant
young
children
often
complic
aom
rsv
significantli
reduc
incid
diseas
piv
vaccin
effect
infant
less
month
age
formalininactiv
vaccin
capabl
induc
neutral
antibodi
protect
anim
model
subunit
vaccin
develop
use
hemagglutininneuraminidas
f
glycoprotein
vaccin
protect
rodent
model
well
toler
seroposit
adult
studi
extens
human
live
attenu
cpt
strain
piv
administ
intranas
spray
protect
anim
model
earli
candid
vaccin
caus
rhinorrhea
wheez
seroneg
young
children
attenu
candid
vaccin
test
seroneg
infant
greater
month
age
vaccin
infect
recipi
induc
serum
hemagglutin
inhibit
hai
antibodi
respons
well
toler
use
anoth
strategi
bovin
piv
type
vaccin
administ
intranas
spray
protect
anim
model
immunogen
well
toler
seroposit
seroneg
children
young
month
age
studi
karron
et
al
seroneg
children
month
age
success
infect
vaccin
viru
demonstr
antibodi
respons
hai
develop
respons
human
infant
less
month
age
vaccin
infecti
recipi
vaccin
induc
hai
antibodi
respons
recipi
immunogen
interfer
note
infant
matern
antibodi
recent
studi
infant
randomli
assign
receiv
vaccin
placebo
intranas
spray
month
age
vaccin
well
toler
first
three
dose
induc
fourfold
rise
hai
antibodi
result
nasal
shed
approxim
vaccine
refin
piv
vaccin
need
effect
vaccin
licens
use
infant
frequent
bacteri
pathogen
associ
aom
pneumonia
nontyp
h
influenza
nthi
moraxella
catarrhali
streptococcu
pyogen
staphylococcu
aureu
vaccin
develop
pathogen
current
vaccin
pneumonia
licens
avail
use
unit
state
first
vaccin
licens
prevent
infect
caus
pneumoniaeiniti
follow
pneumococc
polysaccharid
vaccin
use
children
less
month
age
highest
risk
invas
pneumococc
diseas
aom
polysaccharid
antigen
tcell
independ
reliabl
induc
antibodi
respons
children
less
month
age
contrast
conjug
bacteri
polysaccharid
protein
antigen
induc
tcell
memori
enhanc
immunolog
respons
infant
prototyp
vaccin
h
influenza
type
b
hib
conjug
vaccin
dramat
reduc
incid
invas
hib
infect
includ
mening
unit
state
similar
method
use
manufactur
pneumococc
conjug
vaccin
pcv
contain
seven
common
serotyp
caus
invas
diseas
children
less
year
age
unit
state
prevnar
wyethlederl
philadelphia
pa
licens
unit
state
recommend
univers
use
begin
month
age
seven
serotyp
contain
vaccin
repres
often
resist
penicillin
antibiot
shown
prevent
nasopharyng
acquisit
pneumococc
serotyp
contain
vaccin
doubleblind
random
efficaci
trial
conduct
northern
california
kaiser
permanent
health
system
black
et
al
administ
vaccin
placebo
infant
month
age
intenttotreat
analysi
efficaci
vaccin
prevent
invas
pneumococc
diseas
caus
serotyp
cover
vaccin
ci
aom
primari
endpoint
studi
standard
case
definit
use
intenttotreat
analysi
vaccin
reduc
incid
episod
aom
ci
use
tympanostomi
tube
ci
separ
studi
finland
infant
randomli
assign
receiv
vaccin
placebo
month
age
myringotomi
tympanocentesi
perform
episod
aom
vaccin
reduc
incid
aom
caus
ci
pneumococc
serotyp
ci
pneumococc
serotyp
contain
vaccin
ci
contrast
episod
aom
caus
pneumococc
serotyp
cover
vaccin
increas
investig
found
increas
nasopharyng
carriag
nonvaccin
serotyp
follow
immun
pcv
followup
studi
requir
learn
whether
pneumococc
serotyp
replac
current
strain
caus
aom
strain
develop
resist
expos
antibiot
children
pneumococc
conjug
vaccin
expand
coverag
nine
serotyp
develop
sever
pharmaceut
compani
evalu
number
clinic
trial
although
vaccin
prevent
slightli
episod
aom
vaccin
potenti
nonvaccin
serotyp
becom
preval
still
exist
altern
vaccin
specif
base
pneumococc
protein
may
offer
advantag
prevent
pneumococc
strain
regardless
serotyp
pneumococc
protein
candid
includ
pspa
pneumolysin
psaa
pspc
neuraminidas
hyaluronidas
rat
model
pspa
shown
protect
aom
intranas
immun
fulllength
nativ
pspa
recombin
psaa
reduc
nasal
carriag
pneumococci
mice
protein
administ
combin
greater
effect
mucos
immun
protein
elicit
circul
mucos
antibodi
system
antibodi
pspa
protect
anim
sepsi
one
signific
advantag
use
pspa
vaccin
candid
antibodi
singl
pspa
crossreact
heterolog
pspa
categor
six
clade
use
amino
acid
sequenc
data
pneumococc
strain
synergist
protect
sepsi
mice
observ
pneumolysin
ad
pspa
immun
ultim
like
multipl
pneumococc
protein
combin
human
vaccin
vaccin
bacteri
pathogen
caus
middleear
diseas
develop
specif
nthi
catarrhali
cellsurfac
antigen
nthi
may
use
vaccin
includ
outer
membran
protein
omp
high
molecular
weight
hmw
protein
pili
fimbria
six
major
omp
nthi
label
order
decreas
molecular
weight
bactericid
activ
antibodi
protein
demonstr
abil
protect
infect
enhanc
clearanc
organ
anim
model
variabl
omp
demonstr
signific
heterogen
strain
limit
use
vaccin
candid
greatest
interest
focus
surfac
expos
immunogen
highli
conserv
among
strain
nthi
shown
induc
bactericid
antibodi
enhanc
pulmonari
clearanc
homolog
heterolog
nthi
anim
model
howev
children
prone
frequent
episod
aom
may
recogn
effect
immunogen
hmw
protein
pili
import
attach
nthi
respiratori
epithelium
immun
chinchilla
hmw
protein
pili
provid
degre
protect
aom
passiv
antibodi
protein
protect
chinchilla
aom
mee
due
nthi
potenti
antigen
vaccin
develop
catarrhali
includ
omp
fimbria
lipooligosaccharid
lo
omp
lo
fairli
well
conserv
across
mani
strain
chinchilla
inadequ
evalu
vaccin
candid
catarrhali
shown
antibodi
antigen
protect
develop
aom
kyd
et
al
develop
murin
model
demonstr
enhanc
pulmonari
clearanc
catarrhali
follow
mucos
immun
kill
organ
ubiquit
surfac
protein
elicit
bactericid
antibodi
anim
immun
mice
clear
catarrhali
quickli
respiratori
tract
adult
human
high
titer
antibodi
protein
clinic
trial
protein
progress
cd
porin
omp
enhanc
pulmonari
clearanc
catarrhali
mice
clinic
studi
conduct
surfac
antigen
catarrhali
evalu
potenti
vaccin
candid
much
learn
function
activ
respect
antibodi
signific
progress
made
understand
epidemiolog
pathogenesi
aom
infant
young
children
need
prevent
infect
greater
ever
incid
cost
treat
aom
increas
significantli
recent
year
antibiot
resist
becom
widespread
region
unit
state
use
effect
vaccin
costeffici
way
prevent
aom
viral
vaccin
use
prevent
uri
commonli
preced
aom
influenza
viru
vaccin
reduc
incid
aom
approxim
one
third
influenza
season
vaccin
current
recommend
children
futur
vaccin
rsv
piv
even
greater
effect
reduc
incid
aom
bacteri
vaccin
also
need
prevent
aom
recent
licens
pcv
significantli
reduc
aom
caus
serotyp
contain
vaccin
proteinbas
vaccin
need
cover
strain
pneumococci
vaccin
prevent
aom
caus
nthi
catarrhali
develop
paper
particular
interest
publish
recent
highlight
import
major
import
